Sanofi Shares Drop After End of Development Program for Breast-Cancer Drug
17 August 2022 - 10:15AM
Dow Jones News
By Pierre Bertrand
Sanofi shares fell in early Wednesday trading after the company
discontinued its global clinical development program for
breast-cancer drug amcenestrant.
At 0733 GMT, shares of the French pharmaceutical company traded
4.1% lower to EUR83.01.
An independent data-monitoring committee found that
amcenestrant, which targets a type of advanced or metastatic breast
cancer, didn't satisfy the requirements for continued study and
recommended stopping the trial, Sanofi said.
The decision to shelve the treatment program was based on the
interim review of its Phase 3 Ameera-5 trial. All other trials
involving the drug, including its AMEERA-6 early-stage breast
cancer trial, will be discontinued, Sanofi said.
The end of amcenestrant's development program comes after the
drug's Phase 2 clinical trial failed in March.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
August 17, 2022 04:00 ET (08:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024